

Vyriad, Inc. Appoints Scott Beck as Chief Operating Officer



A seasoned executive with deep knowledge and experience of biotechnology and healthcare operations.

Vyriad, Inc., a biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, announces the appointment of Scott Beck, MBA as Chief Operating Officer.

During the past three decades Mr. Beck held many leadership roles at Mayo Clinic, covering multiple aspects of the discovery, translation and application of novel biotechnologies, and their commercial development. He played a major part in the early development of the oncolytic virotherapy platforms licensed to Vyriad. He was most recently the COO for Laboratory Services at Mayo Clinic where he oversaw an extensive worldwide reference laboratory business.

"I am delighted to welcome Scott to the Vyriad team. He is an outstanding operations leader and a good friend. His proven leadership and relentless focus on execution will help realize our Company's goals," said Dr. Stephen Russell, Vyriad's Chief Executive Officer.

"I am excited to join the Vyriad team and advance our vision of healing cancer patients with engineered virotherapies. The company has come a long way in a short period of time under Steve's leadership, and I look forward to helping grow our patient impact," said Mr. Beck.

Source: Vyriad

. _

Published on: Tue, 13 Sep 2022